EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa?

Klodeta Kura iD, Philip Milton, Jonathan I D Hamley, Martin Walker, Didier K Bakajika, Eric M Kanza, Nicholas O Opoku, Hayford Howard, Maurice M Nigo, Sampson Asare, George Olipoh, Simon K Attah und 9 weitere

Philosophical Transactions of the Royal Society B · 09.10.2023 · 378 (1887)

DOI: 10.1098/rstb.2022.0277 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Philosophical Transactions of the Royal Society B, online erschienen am 21.08.2023. Verfasst von Klodeta Kura und 20 weiteren Autor:innen. Beteiligte Einrichtung: London Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College Londo…. Hauptthemen laut MEDLINE: Onchocerciasis. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, Medical Research Council, UK Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidemiological and modelling studies suggest that elimination of Onchocerca volvulus transmission (EoT) throughout Africa may not be achievable with annual mass drug administration (MDA) of ivermectin alone, particularly in areas of high endemicity and vector density. Single-dose Phase II and III clinical trials demonstrated moxidectin's superiority over ivermectin for prolonged clearance of O. volvulus microfilariae. We used the stochastic, individual-based EPIONCHO-IBM model to compare the probabilities of reaching EoT between ivermectin and moxidectin MDA for a range of endemicity levels (30 to 70% baseline microfilarial prevalence), treatment frequencies (annual and biannual) and therapeutic coverage/adherence values (65 and 80% of total population, with, respectively, 5 and 1% of systematic non-adherence). EPIONCHO-IBM's projections indicate that biannual (six-monthly) moxidectin MDA can reduce by half the number of years necessary to achieve EoT in mesoendemic areas and might be the only strategy that can achieve EoT in hyperendemic areas. Data needed to improve modelling projections include (i) the effect of repeated annual and biannual moxidectin treatment; (ii) inter- and intra-individual variation in response to successive treatments with moxidectin or ivermectin; (iii) the effect of moxidectin and ivermectin treatment on L3 development into adult worms; and (iv) patterns of adherence to moxidectin and ivermectin MDA. This article is part of the theme issue ‘Challenges in the fight against neglected tropical diseases: a decade from the London Declaration on NTDs’.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OnchocerciasisHumansIvermectinMass Drug AdministrationAfricaNeglected DiseasesMacrolides

Stichwörter der Autor:innen

MDAivermectinmass drug administrationmodellingmoxidectinonchocerciasis

Substanzen

IvermectinmoxidectinMacrolides

Autor:innen und Institutionen

  • London Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London W2 1PG, UK.
  • MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London W2 1PG, UK.
  • Department of Pathobiology and Population Sciences, Royal Veterinary College, Hatfield AL9 7TA, UK.
  • Expanded Special Project for Elimination of Neglected Tropical Diseases (ESPEN), African Regional Office of the World Health Organization (WHO/AFRO/ESPEN), Brazzaville, Democratic Republic of Congo.
  • Programme Nationale de Lutte contre les Maladies Tropicales Négligées à Chimiothérapie Préventive (PNLMTN-CTP), Ministère de la Santé Publique, Kinshasa, Democratic Republic of the Congo.
  • Department of Epidemiology and Biostatistics, School of Public Health, University of Health and Allied Sciences, Hohoe, Ghana.

ORCID-Profile: Klodeta Kura, Maria-Gloria Basáñez

Förderung

  • World Health Organization
  • Medical Research Council
  • UK Medical Research Council
  • Bill and Melinda Gates Foundation

Zitieren

APA

Kura, K., Milton, P., Hamley, J. I. D., Walker, M., Bakajika, D. K., Kanza, E. M., Opoku, N. O., Howard, H., Nigo, M. M., Asare, S., Olipoh, G., Attah, S. K., Mambandu, G. L., Kennedy, K. K., Kataliko, K., Mumbere, M., Halleux, C. M., Hopkins, A., Kuesel, A. C., …, & Basáñez, M. G. (2023). Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa?. Philosophical Transactions of the Royal Society B, 378(1887). https://doi.org/10.1098/rstb.2022.0277

Vancouver

Kura K, Milton P, Hamley JID, Walker M, Bakajika DK, Kanza EM, et al. Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa?. Philosophical Transactions of the Royal Society B. 2023;378(1887). doi:10.1098/rstb.2022.0277

BibTeX
@article{Kura2023,
  author = {Kura, Klodeta and Milton, Philip and Hamley, Jonathan I D and Walker, Martin and Bakajika, Didier K and Kanza, Eric M and Opoku, Nicholas O and Howard, Hayford and Nigo, Maurice M and Asare, Sampson and Olipoh, George and Attah, Simon K and Mambandu, Germain L and Kennedy, Kambale Kasonia and Kataliko, Kambale and Mumbere, Mupenzi and Halleux, Christine M and Hopkins, Adrian and Kuesel, Annette C and Kinrade, Sally and Basáñez, Maria-Gloria},
  title = {Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa?},
  journal = {Philosophical Transactions of the Royal Society B},
  year = {2023},
  volume = {378},
  number = {1887},
  doi = {10.1098/rstb.2022.0277}
}
Kostenlos starten →